The rapid expansion of antibody-drug conjugates (ADCs) and novel emerging bioconjugates such as antibody-oligonucleotide conjugates (AOCs) is driving unprecedented CMC complexity. ADCs are a clear success story as they move towards earlier lines of treatment and into non-traditional indications. However, successful development of a bioconjugate therapeutic is no longer just about design innovation. Flawless development and scale-up of complex conjugation technologies is required to deliver on the design promise. Manufacturing expertise, and the ability to reliably deliver GMP product for clinical development and into commercial supply are strategic advantages.
Conor Barry, PhD, Head of R&D – Bioconjugates & Large Molecules at Piramal Pharma Solutions (Grangemouth, UK), will present practical, data-driven insights from integrated bioconjugate programs spanning early development through commercial manufacture. Attendees will gain:
- A framework for selecting and optimizing conjugation strategies, including site-specific and enzymatic approaches, to control DAR and product heterogeneity
- Case study-driven solutions to payload-linker and analytical challenges, including impurity resolution, chromatography design, and LC-MS characterization in complex systems such as AOCs
- An integrated CMC perspective on aligning process development, scale-up, and global manufacturing to enable rapid and robust clinical supply
As bioconjugate modalities become more sophisticated, success depends on deep technical expertise combined with tightly integrated development and manufacturing strategies. This webinar will provide actionable insights to help you de-risk complex programs and improve speed to clinic and beyond. Register now to engage with cutting-edge approaches in bioconjugate CMC and stay ahead of evolving technical demands.